Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience
Zolbetuximab plus chemotherapy was administered to real-world patients with CLDN18.2-positive AGC with acceptable safety profiles and showed preliminary antitumor efficacy. Nevertheless, some adverse events warrant careful monitoring.
Authors
- Shota Fukuoka (ORCID: https://orcid.org/0000-0001-9460-4486)
- Akira Ooki (ORCID: https://orcid.org/0000-0001-7618-5775)
- Keitaro Shimozaki (ORCID: https://orcid.org/0000-0002-4559-5699)
- Hiroki Osumi (ORCID: https://orcid.org/0000-0002-4742-0446)
- Koichiro Yoshino (ORCID: https://orcid.org/0000-0002-9877-9336)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Eiji Shinozaki (ORCID: https://orcid.org/0000-0002-7448-5894)
- Shohei Udagawa (ORCID: https://orcid.org/0009-0005-2225-7346)
- Mariko Ogura (ORCID: https://orcid.org/0000-0002-1004-8425)
- Kensei Yamaguchi (ORCID: https://orcid.org/0000-0001-6887-5709)
- Kaoru Yoshikawa
- Keisho Chin
Institutions
- Keio University (JP)
- The Cancer Institute Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1007/s00432-025-06406-4
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00